Skip to main content
Article thumbnail
Location of Repository

Peroxisome Proliferator-Activated Receptors in HCV-Related Infection

By Sébastien Dharancy, Maud Lemoine, Philippe Mathurin, Lawrence Serfaty and Laurent Dubuquoy

Abstract

The topic of peroxisome proliferator-activated receptors has been developed in the field of hepatology allowing envisaging therapeutic strategies for the most frequent chronic liver diseases such as chronic infection with hepatitis C virus (HCV). PPARs contribute to wide physiological processes within the liver such as lipid/glucid metabolisms, inflammatory response, cell differentiation, and cell cycle. In vitro experiments and animal studies showed that PPARα discloses anti-inflammatory property, and PPARγ discloses anti-inflammatory, antifibrogenic, and antiproliferative properties in the liver. Experimental and human studies showed impaired PPARs expression and function during HCV infection. The available nonhepatotoxic agonists of PPARs may constitute a progress in the therapeutic management of patients chronically infected with HCV

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:2662434
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2005). a t z i u ,A .H e u r t i e r ,L .B o n y h a y ,T .P o y n a r d ,a n dP .G i r a l , “Review article: an unexpected virus-host interaction—the hepatitis C virus-diabetes link,”
    2. (2005). A.Yamaguchi,S.Tazuma,T.Nishioka,etal.,“HepatitisCvirus core protein modulates fatty acid metabolism and thereby causes lipid accumulation
    3. (2006). Absence of peroxisome proliferators-activated receptors (PPAR)α enhanced
    4. (2001). Activation of retinoic X receptor and peroxisome proliferator-activatedPPAR Research 5 receptor-γ inhibits nitric oxide and tumor necrosis factor-α production
    5. (1997). Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficientmice,”TheJournalofBiologicalChemistry,
    6. (2005). and type II diabetes mellitus: a prospective cross-sectional study,”
    7. (2002). Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro,”
    8. (2000). Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate,”
    9. (1992). Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors,”
    10. (1997). Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators,”
    11. (2002). Delayed liver regeneration in peroxisome proliferator-activated receptor-α-null mice,”
    12. (2001). e r f a t y ,T .A n d r e a n i ,P .G i r a l ,N .C a r b o n e l l ,O .C h a -zouill` eres, and
    13. (1999). Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-α,”
    14. (1996). Gonzalez,andW.Wahli,“ThePPARα–leukotrieneB4 pathway to inflammation control,”
    15. (1996). Hepatic stellate cells,”
    16. (2002). Hepatocellular carcinoma and hepatitis
    17. (2001). Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferatoractivated receptor α in HepG2 cells,”
    18. (2005). Impaired expression of the peroxisome proliferator-activated receptor alphaduringhepatitisCvirusinfection,”Gastroenterology,vol.
    19. (1998). L e e ,S .L i m ,S .B a s s i l i a n ,E .A .B e r g n e r ,a n dJ . Edmond, “Fatty acid cycling in human hepatoma cells and theeffectsoftroglitazone,”
    20. (2000). Ligands of peroxisome proliferator-activated receptor γ modulate profi-brogenic and proinflammatory actions in hepatic stellate cells,”
    21. (2003). Liver fibrosis—from bench to bedside,”
    22. (2002). Natural history of chronic hepatitis
    23. (1999). Nuclear Receptors Nomenclature Committee, “A unified nomenclature system for the nuclear receptor superfamily,”
    24. (1999). Organization, “Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board,
    25. (2004). P.Colville-Nash,D.Willis,J.Papworth,etal.,“Theperoxisome proliferator-activated receptor α activator, Wy14,643, is antiinflammatory in vivo,”
    26. (2000). P.Delerive,P.Gervois,J.-C.Fruchart,andB.Staels,“Induction of IκBα expression as a mechanism contributing to the antiinflammatory activities of peroxisome proliferator-activated receptor-α activators,”
    27. (2000). P.Gervois,I.P.Torra,J.-C.Fruchart,andB.Staels,“Regulation of lipid and lipoprotein metabolism by PPAR activators,”
    28. (2001). Peroxisomal β-oxidation and steatohepatitis,”
    29. (2006). Peroxisome proliferator-activated receptor-α and -γ mRNA levels are reduced
    30. (2000). Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation,”
    31. (2000). Peroxisome proliferator-activated receptors and hepatic stellate cell activation,”
    32. (2000). Peroxisome proliferator-activated receptors: insight into multiple cellular functions,”
    33. (2002). PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantationassociated arteriosclerosis,”
    34. (1998). PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,”
    35. (2004). PPARα ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats,”
    36. (2002). PPARγ dependent regulation of hepatic stellate cells,”
    37. (2000). R e d d y ,a n dM .S .R a o ,“ D e f e c ti np e r o x i s o m ep r o l i f e r a t o r -activated receptor α-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting,”
    38. (2004). Reduction of serum HCV RNA titer by bezafibrate therapy in patients with chronic hepatitis
    39. (2002). Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors,”
    40. (2004). Repression of IFN-γ expression by peroxisome proliferator-activated receptor γ,”
    41. (1990). s s e m a n na n dS .G r e e n ,“ A c t i v a t i o no fam e m b e ro f the steroid hormone receptor superfamily by peroxisome proliferators,”
    42. (2001). Study of effectiveness of bezafibrate in the treatment of chronic hepatitis
    43. (2000). The nuclear receptor PPARγ a n di m m u n o r e g u l a t i o n :P P A R γ mediates inhibition of helper T cell responses,”
    44. (1998). The peroxisome proliferator-activated receptor-γ is a
    45. (2002). WY14,643, a PPARα ligand, has profound effects on immune responses in vivo,”
    46. (2000). Y a n g ,L .H .W a n g ,T .C h e n ,e ta l . ,“ A c t i v a t i o no f humanTlymphocytesisinhibitedbyperoxisomeproliferatoractivated receptor γ (PPARγ) agonists. PPARγ co-association with transcription factor NFAT,”

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.